Article Text

PDF
Extended report
Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden
  1. A Gülfe1,
  2. L E Kristensen1,
  3. T Saxne1,
  4. L T H Jacobsson2,
  5. I F Petersson3,
  6. P Geborek1
  1. 1
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
  2. 2
    Department of Rheumatology, Malmö University Hospital, Malmö, Sweden
  3. 3
    South Sweden Musculoskeletal Research Centre, Department of Orthopedics, Lund University Hospital, Lund, Sweden
  1. Correspondence to Dr P Geborek, Department of Rheumatology, Lund University Hospital, SE-221 85 Lund, Sweden; Pierre.geborek{at}med.lu.se

Abstract

Background: Rheumatoid arthritis (RA), psoriatic arthritis (PsA) and other spondylarthritides impose a great impact on the individual in addition to the costs on society, which may be reduced by effective pharmacological treatment. Industry-independent health economic studies should complement studies sponsored by industry.

Objective: To study secular trends in baseline health utilities in patients commencing tumour necrosis factor (TNF) blockade for arthritis in clinical practice over 7 years; to address utility changes during treatment; to investigate the influence of previous treatment courses; to study the feasibility of health utility measures and to compare them across diagnostic entities.

Methods: EuroQoL 5 dimensions (EQ-5D) utility data were collected from a structured clinical follow-up programme of anti-TNF-treated patients with RA (N  =  2554), PsA (N  =  574) or spondylarthritides (N  =  586). Time trends were calculated. Completer analysis was used.

Results: There were weak or non-significant secular trends for increasing baseline utilities over time for RA, PsA and spondylarthritides. The maximum gain in utilities had already occurred after 2 weeks for all diagnoses and remained stable for patients remaining on therapy. The first and second anti-TNF courses performed similarly.

Conclusions: Utilities at inclusion remained largely unchanged for RA, PsA and spondylarthritides over 7 years. Improvement occurred early during treatment and not beyond 6 weeks at the group level. Improvement during the first course was not consistently greater than the second. There were no major differences between RA, PsA and spondylarthritides. EQ-5D proved feasible and applicable across these diagnoses. These “real world” data may be useful for health economic modelling.

Statistics from Altmetric.com

Footnotes

  • ▸ Additional supplemental table 1 is published online only at http://ard.bmj.com/content/vol69/issue2

  • Funding This study was supported by grants from Österlund and Kock Foundations, King Gustav V 80 year fund, Lund University Hospital, Region Skåne, Faculty of Medicine, Lund University and Reumatikerförbundet.

  • Competing interests None.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.